Adeno-associated viral (aav) vectors for tissue-targeted expression of therapeutic genes
US-2024285804-A1 · Aug 29, 2024 · US
US10676512B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10676512-B2 |
| Application number | US-201515508662-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 4, 2015 |
| Priority date | Sep 5, 2014 |
| Publication date | Jun 9, 2020 |
| Grant date | Jun 9, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present disclosure relates to a novel modified RNA polymerase sigma factor A (SigA) polypeptide; a polynucleotide encoding the same; a microorganism containing the polypeptide; and a method for producing L-lysine using the microorganism.
Opening claim text (preview).
The invention claimed is: 1. A modified polypeptide having RNA polymerase sigma factor A activity and the amino acid sequence set forth in SEQ ID NO: 2 but with one or two amino acid substitutions, wherein at least one of the one or two amino acid substitutions is selected from the group consisting of a substitution of the 136 th amino acid with glycine; a substitution of the 254 th amino acid with asparagine; a substitution of the 268 th amino acid with serine; a substitution of the 281 st amino acid with serine; a substitution of the 381 st amino acid with arginine; a substitution of the 429 th amino acid with arginine; a substitution of the 447 th amino acid with histidine; a substitution of the 451 st amino acid with isoleucine; a substitution of the 455 th amino acid with valine; a substitution of the 479 th amino acid with arginine; a substitution of the 483 rd amino acid with arginine; a substitution of the 488 th amino acid with threonine; and a substitution of the 491 st amino acid with arginine. 2. The modified polypeptide according to claim 1 , wherein the modified polypeptide has an amino acid sequence selected from the group consisting of the amino acid sequences set forth in SEQ ID NOS: 12 to 22. 3. A polynucleotide encoding the modified polypeptide of claim 1 . 4. A host cell comprising the polynucleotide of claim 3 . 5. A microorganism of the genus Corynebacterium having enhanced L-lysine producibility, comprising a modified polypeptide having RNA polymerase sigma factor A activity and the amino acid sequence set forth in SEQ ID NO: 2 but with one or two substitutions in SEQ ID NO:2, wherein at least one of the one or two substitutions is selected from the group consisting of a substitution of the 136 th amino acid with glycine; a substitution of the 254 th amino acid with asparagine; a substitution of the 268 th amino acid with serine; a substitution of the 281 st amino acid with serine; a substitution of the 381 st amino acid with arginine; a substitution of the 429 th amino acid with arginine; a substitution of the 447 th amino acid with histidine; a substitution of the 451 st amino acid with isoleucine; a substitution of the 455 th amino acid with valine; a substitution of the 479 th amino acid with arginine; a substitution of the 483 rd amino acid with arginine; a substitution of the 488 th amino acid with threonine; and a substitution of the 491 st amino acid with arginine. 6. The microorganism according to claim 5 , wherein the microorganism is Corynebacterium glutamicum. 7. A method for producing L-lysine, comprising: (a) culturing the microorganism according to claim 5 in a medium; and (b) recovering L-lysine from the cultured microorganism or the cultured medium.
Related publications grouped by family.
Answers are generated from the same data shown on this page.